Both in Diagnostics
Immucell vs Myriad Genetics
Over the past year ICCC returned +63.6% and MYGN returned −27.0%; their daily moves had a correlation of -0.01.
ICCC +63.6% MYGN −27.0%Growth of $1, one year, split-adjusted
| Metric | ICCC | MYGN |
|---|---|---|
| Price | $10.16 | $5.97 |
| Market cap | $92.3M | $571.0M |
| Today | −0.88% | −1.16% |
| 1 month | +1.9% | +39.5% |
| 6 months | +17.3% | +45.3% |
| Year to date | +65.2% | −2.9% |
| 1 year | +63.6% | −27.0% |
| Revenue growth (YoY) | +11.5% | −10.5% |
| Gross margin | 33.9% | 66.6% |
| Net margin | 25.5% | −22.7% |
| P/E (TTM) | 117.2× | — |
| Price / sales | 3.0× | 0.7× |
| Net cash | $557.3K | -$5.5M |
| Dividend yield | — | — |
| Volatility (60d) | 38.4% | 85.1% |
| Short % of float | 0.3% | 10.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).